Net Profit Soars Nearly 300%! Lepu Medical Bets Big on Brain-Computer Interface with Dual-Track Strategy

The annual report shows that in 2025, the company achieved operating revenue of 6.483 billion yuan, a year-on-year increase of 6.22%; the net profit attributable to parent company was 962 million yuan, a year-on-year increase of 289.57%. Against the backdrop of performance recovery and stabilization of core business under pressure, brain-computer interface is becoming a key variable for this enterprise to break through growth bottlenecks and open up long-term growth space.

Lepu Medical's brain-computer interface layout has, from the outset, followed a dual-track approach of non-invasive and interventional invasive methods, relying on two subsidiaries for clear division of labor and technical complementarity.

In the field of non-invasive brain-computer interfaces (BCI), Lepu Medical's key player is its holding subsidiary, RxHEAL. As one of the earliest companies in China to engage in non-invasive BCI research and development, RxHEAL has launched the world’s first commercialized BCI hand function rehabilitation robot system. Multiple products, including digital electroencephalographs and rehabilitation training devices, have received NMPA approval. These products are now utilized in over a hundred renowned medical institutions and scientific research institutes across China, generating small-scale revenue. The company is currently focusing on next-generation non-invasive BCI products capable of completing EEG sensing, analysis, intervention, and forming a closed loop. Targeting critical demand scenarios such as neurological rehabilitation, cognitive rehabilitation, and pediatric rehabilitation, the company has a clear path to commercialization.

In the field of invasive brain-computer interfaces with higher technological barriers, Lepu Medical Electronic Instrument Co., Ltd. has taken on the core task of overcoming challenges. This company, whose origins can be traced back to 1986, has long been deeply engaged in active implantable medical devices. It has achieved several breakthroughs in China for the first time in the field of cardiac pacemakers, with over 30,000 cumulative implants. The company possesses mature capabilities in the research and development, production, and clinical transformation of implantable devices.

Currently, Lepu Medical's implantable multi-channel brain-computer interface product has completed animal experiments and officially entered the ITT clinical research stage in humans, ranking among the first-tier progress of medical device companies in China.

More importantly, Lepu Medical did not advance brain-computer interface technology in isolation, but ratherNeuromodulation Product Matrix as the Underlying Support: The company's implantable deep brain stimulation system (DBS) has obtained the registration certificate, completed the listing in 2-3 provinces, with a target sales volume of 1,000 units by 2026, corresponding to revenue of 50 million yuan; vagus nerve stimulator (VNS), spinal cord stimulation system (SCS), and sacral nerve stimulation system (SNM) are all in the clinical stage.

This means that Lepu's brain-computer interface is not merely a signal-reading device but is deeply integrated with neuromodulation, possessing closed-loop capabilities from sensing, decoding to precise stimulation, making it a typical...Medical-Grade Brain-Computer Interface, forming a clear distinction from consumer-grade and experimental products.

The current brain-computer interface track is not short of technically impressive startups, but the competitiveness of Lepu Medical is more reflected inComprehensive capabilities in industrialization, clinical translation, and commercializationAbove all, this is also the core value for traditional medical device giants to enter the cutting-edge field.